A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors

Back to Search
Print
Bookmark Trial

NCT00615446

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Boston, Massachusetts, 02114, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Solid Tumors
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists

- Patient has good performance status (ECOG 0 or 1)

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Prior treatment with either gemcitabine or SU011248


- Hypertension that cannot be controlled by medications

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Solid TumorsErlotinib and Temsirolimus for Solid Tumors
NCT00770263
  1. St. Louis, Missouri
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Solid TumorsTemsirolimus and Pazopanib in Patients With Advanced Solid Tumors
NCT01072890
  1. Sacramento, California
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Solid TumorsInteraction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers
NCT00583063
  1. Chicago, Illinois
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Solid TumorsRollover Protocol for Prior SU011248 Protocols
NCT00798889
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Los Angeles, California
  5. Los Angeles, California
  6. San Francisco, California
  7. San Francisco, California
  8. Santa Monica,, California
  9. Aurora, Colorado
  10. Indianapolis, Indiana
  11. Boston, Massachusetts
  12. Boston, Massachusetts
  13. Boston, Massachusetts
  14. Ann Arbor, Michigan
  15. Detroit, Michigan
  16. Farmington Hills, Michigan
  17. Minneapolis, Minnesota
  18. St. Louis, Missouri
  19. Albuquerque, New Mexico
  20. Albuqurque, New Mexico
  21. New York, New York
  22. New York, New York
  23. New York, New York
  24. Durham, North Carolina
  25. Cleveland, Ohio
  26. Philadelphia, Pennsylvania
  27. Myrtle Beach, South Carolina
  28. Franklin, Tennessee
  29. Gallatin, Tennessee
  30. Hermitage, Tennessee
  31. Lebanon, Tennessee
  32. Murfreesboro, Tennessee
  33. Nashville, Tennessee
  34. Nashville, Tennessee
  35. Nashville, Tennessee
  36. Nashville, Tennessee
  37. Nashville, Tennessee
  38. Nashville, Tennessee
  39. Smyrna, Tennessee
  40. Dallas, Texas
  41. Houston, Texas
  42. Madison, Wisconsin
  43. Randwick, New South Wales
  44. East Melbourne, Victoria
  45. Heidelberg, Victoria
  46. Montreal, Quebec
  47. Villejuif Cedex,
  48. Thessaloniki,
  49. Milano,
  50. Milano,
  51. Nijmegen, Gld
  52. Singapore,
  53. Lund,
  54. Stockholm,
  55. St. Gallen,
  56. Leeds,
  57. London,
  58. London,
  59. Newcastle-Upon-Tyne,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors
Official Title  ICMJE A Phase 1 Study Of SU011248 And Gemcitabine In Patients With Advanced Solid Tumors
Brief Summary This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with gemcitabine in patients with advanced solid tumors
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Solid Tumors
Intervention  ICMJE Drug: SU011248; Gemcitabine
Dose finding study using SU011248 (sunitinib) daily by oral capsule in 4/2 (administered for 4 out of every 6 weeks) or 2/1 (administered for 2 out of every 3 weeks) schedule with gemcitabine administered on Days 1, 8, 22 and 29 on Schedule 4/2 and Days 1 and 8 on Schedule 2/1 until progression or unacceptable toxicity
Other Name: Sutent, sunitinib, SU11248, Gemzar
Study Arms  ICMJE Experimental: A
Intervention: Drug: SU011248; Gemcitabine
Publications * Michaelson MD, Zhu AX, Ryan DP, McDermott DF, Shapiro GI, Tye L, Chen I, Stephenson P, Patyna S, Ruiz-Garcia A, Schwarzberg AB. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. Br J Cancer. 2013 Apr 16;108(7):1393-401. doi: 10.1038/bjc.2013.96. Epub 2013 Mar 19.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 15, 2009)		44
Original Estimated Enrollment  ICMJE
 (submitted: February 1, 2008)		50
Actual Study Completion Date  ICMJE May 2009
Actual Primary Completion Date May 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients with diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists
  • Patient has good performance status (ECOG 0 or 1)

Exclusion Criteria:

  • Prior treatment with either gemcitabine or SU011248
  • Hypertension that cannot be controlled by medications
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00615446
Other Study ID Numbers  ICMJE A6181041
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP